Drug details:
Molecular formula: C₂₁H₂₅NO₇

Standard name: N-methyl-3-[3-methyl-4-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]benzamide

Curated SMILES: CNC(=O)C1=CC(C2=CC(C)=C(OC3OC(CO)C(O)C(O)C3O)C=C2)=CC=C1

Evidence for compound's anti-virulence activity:

Escherichia
Related VF: Type 1 fimbriae
Target: FimH
Drug effect: Bound to the FimH lectin domain to interfere with bacterial adhesion, invasion and biofilm formation.
Max phase: Preclinical (in vivo)
Publications:
Cusumano CK, et al., 2011. Treatment and prevention of urinary tract infection with orally active FimH inhibitors. Sci Transl Med 3(109):109ra115.
Jarvis C, et al., 2016. Antivirulence Isoquinolone Mannosides: Optimization of the Biaryl Aglycone for FimH Lectin Binding Affinity and Efficacy in the Treatment of Chronic UTI. ChemMedChem 11(4):367-73.